Heart Failure

Heart Failure – Comprehensive Study Guide for Medical Students

Heart failure (HF) is a common, chronic, progressive clinical syndrome of the cardiovascular system characterized by the heart’s inability to pump sufficient blood to meet the body’s metabolic demands, or can do so only at elevated filling pressures. It is a core topic in internal medicine and cardiology and a major cause of morbidity, mortality, and healthcare utilization worldwide.^[7]

Definition

Heart failure is defined as a clinical syndrome with typical symptoms (e.g., dyspnea, fatigue) and signs (e.g., elevated JVP, pulmonary crackles, peripheral edema) caused by a structural and/or functional cardiac abnormality, resulting in reduced cardiac output and/or elevated intracardiac pressures at rest or during stress.^[7]

HF is commonly subclassified by left ventricular ejection fraction (LVEF):

• Heart failure with reduced EF (HFrEF): LVEF < 40% – systolic dysfunction.
• Heart failure with mildly reduced EF (HFmrEF): LVEF 41–49%.
• Heart failure with preserved EF (HFpEF): LVEF ≥ 50% with evidence of diastolic dysfunction/raised filling pressures.

Epidemiology

HF is a major public health problem with increasing prevalence due to population aging and improved survival after myocardial infarction and other cardiac diseases.^[7]

• Prevalence: Roughly 1–2% of the adult population in high‑income countries, rising to >10% among those ≥70 years.
• Age: Incidence and prevalence increase sharply with age; HF is a leading cause of hospitalization in older adults.
• Sex: HFrEF more common in men, HFpEF relatively more common in older women.
• Burden: High rates of rehospitalization, impaired quality of life, and substantial healthcare costs; frequent comorbidities include ischemic heart disease, hypertension, diabetes, CKD, AF, and COPD.^[7]

Pathophysiology

Primary Cardiac Abnormalities

HF develops when structural or functional cardiac abnormalities impair the ability of the ventricle(s) to fill with or eject blood:

• Systolic dysfunction (HFrEF): Impaired contractility due to loss of viable myocardium (e.g., ischemic cardiomyopathy), dilated cardiomyopathy, myocarditis, or cardiotoxic drugs.
• Diastolic dysfunction (HFpEF): Impaired relaxation and increased ventricular stiffness (e.g., long‑standing hypertension with LVH, restrictive cardiomyopathy, infiltrative disease, aging myocardium).
• Valvular disease: Volume or pressure overload from regurgitant or stenotic lesions (e.g., aortic stenosis, mitral regurgitation).
• Arrhythmias: Persistent tachyarrhythmias (e.g., AF with RVR) or bradyarrhythmias can precipitate or worsen HF.

Hemodynamic Changes

• Reduced cardiac output: In HFrEF, decreased stroke volume from impaired contractility; in HFpEF, stroke volume is limited by reduced LV filling and increased stiffness.
• Elevated filling pressures: Increased LV end‑diastolic pressure transmits backward to pulmonary veins (→ pulmonary congestion) and, in right‑sided HF, to systemic veins (→ peripheral edema, hepatomegaly).
• Ventricular remodeling: Changes in size, shape, and structure of the LV (eccentric hypertrophy in volume overload, concentric in pressure overload) further impair function over time.

Neurohormonal Activation

Compensatory mechanisms initially maintain perfusion but become maladaptive chronically.^[7]

• Sympathetic nervous system (SNS): Increases heart rate, contractility, and peripheral vasoconstriction; chronically leads to tachycardia, arrhythmias, myocardial oxygen demand, and apoptosis.
• Renin–angiotensin–aldosterone system (RAAS): Promotes vasoconstriction (angiotensin II) and sodium/water retention (aldosterone), worsening congestion and remodeling.
• Arginine vasopressin (ADH): Enhances free water retention, contributing to hyponatremia.
• Natriuretic peptides (BNP, NT‑proBNP): Counter‑regulatory hormones promoting natriuresis and vasodilation; elevated levels are a hallmark of HF and used diagnostically.

Right‑Sided and High‑Output Heart Failure

• Right‑sided HF: Often secondary to left‑sided HF, pulmonary hypertension, or right‑sided structural disease (e.g., RV infarct). Leads to systemic venous congestion.
• High‑output HF: Cardiac output is elevated but still insufficient to meet metabolic demands (e.g., severe anemia, thyrotoxicosis, AV fistula, beriberi). The heart eventually fails under chronic volume overload.

Clinical Presentation

Symptoms

Symptoms vary by acuity (chronic vs acute decompensation) and whether left‑ or right‑sided features predominate.

• Dyspnea: Exertional dyspnea is often the earliest symptom.
• Orthopnea: Dyspnea when lying flat; quantified by number of pillows used.
• Paroxysmal nocturnal dyspnea (PND): Sudden nighttime dyspnea waking the patient from sleep.
• Fatigue, reduced exercise tolerance: Due to reduced cardiac output and skeletal muscle changes.
• Peripheral edema: Swelling of ankles/legs, sacral edema in bed‑bound patients.
• Abdominal symptoms: Early satiety, right upper quadrant discomfort (hepatic congestion), anorexia, nausea.
• Other: Nocturia, weight gain from fluid retention, sometimes weight loss/cachexia in advanced disease.

Signs

• General: Tachycardia, tachypnea, cachexia in advanced HF.
• Vital signs: Hypotension or narrow pulse pressure in severe HF; may be hypertensive early in decompensation.
• Jugular venous distention (JVD): Elevated JVP with positive hepatojugular reflux.
• Lung exam: Bilateral basal crackles (rales), possible wheeze (“cardiac asthma”), dullness if pleural effusion present.
• Cardiac exam: Displaced, diffuse apex beat (LV enlargement), S3 gallop (classically HFrEF), S4 (stiff ventricle), murmurs of underlying valvular disease.
• Peripheral edema: Pitting edema of lower extremities; sacral or scrotal edema in severe cases.
• Hepatic congestion: Hepatomegaly, tender liver, sometimes ascites.

Functional Classification

NYHA functional class (symptom‑based):

• Class I: No limitation of physical activity.
• Class II: Slight limitation; ordinary activity causes symptoms.
• Class III: Marked limitation; less‑than‑ordinary activity causes symptoms.
• Class IV: Symptoms at rest or with minimal activity.

Diagnosis

Diagnosis integrates clinical evaluation with investigations demonstrating structural/functional cardiac abnormalities and elevated filling pressures or neurohormonal markers.^[7]

Initial Clinical Assessment

• History: Symptoms, onset and progression, risk factors (hypertension, CAD, diabetes, valvular disease, cardiotoxic drugs, family history), triggers (infection, dietary indiscretion, non‑adherence, arrhythmias).
• Physical exam: Evaluate volume status, perfusion, and signs of underlying etiologies (e.g., murmurs, stigmata of ischemic or valvular disease).

Laboratory Tests

• Basic labs: CBC, CMP (electrolytes, renal function, liver enzymes), fasting lipids, glucose/HbA1c, TSH, iron studies as indicated.
• BNP or NT‑proBNP: Elevated in HF and useful to rule out HF in dyspneic patients when levels are low. Levels correlate with prognosis and are incorporated into diagnostic and management pathways.^[7]
• Cardiac troponins: Assess for acute coronary syndrome or ongoing myocardial injury.

Electrocardiogram (ECG)

• Often abnormal in HF: evidence of prior MI, LVH, bundle branch blocks, atrial fibrillation or flutter, other arrhythmias.
• Helps guide etiology (ischemic vs non‑ischemic) and management (e.g., QRS duration for CRT eligibility).

Chest X‑ray

• Cardiomegaly: Increased cardiothoracic ratio suggestive of chronic HF.
• Pulmonary congestion: Vascular redistribution (cephalization), interstitial edema (Kerley B lines), alveolar edema (“bat‑wing” pattern), pleural effusions.

Echocardiography (Cornerstone)

Transthoracic echocardiography is essential to confirm HF, classify EF, and identify underlying structural disease.^[7]

• LVEF and global systolic function: Diagnose HFrEF vs HFpEF.
• Chamber size and wall thickness: LV dilation, concentric hypertrophy, RV function.
• Valvular abnormalities: Stenosis or regurgitation, pulmonary hypertension estimates.
• Diastolic function: E/e′ ratio, LA size, filling patterns for HFpEF assessment.
• Regional wall motion abnormalities: Suggest ischemic etiology.

Additional Imaging and Tests

• Coronary angiography/CT coronary angiography: Evaluate for ischemic heart disease in appropriate patients.
• Cardiac MRI: Detailed assessment of function, volumes, tissue characterization (e.g., myocarditis, infiltrative disease, scar extent).
• Stress testing: Ischemia evaluation, functional capacity, often with imaging.
• Right heart catheterization: Hemodynamic assessment in unclear cases or pre‑advanced therapies (LVAD, transplant).

Diagnostic Criteria (Clinical)

Most guidelines emphasize:

• Typical HF symptoms and signs, plus
• Objective evidence of cardiac structural/functional abnormality or elevated natriuretic peptides.

Management

Management aims to relieve symptoms, reduce hospitalizations, slow disease progression, and improve survival. It includes lifestyle measures, pharmacologic therapy, device/interventional strategies, and management of comorbidities.^[7]

General Principles

• Identify and treat underlying etiology (e.g., revascularization for ischemia, valve surgery, control of hypertension, cessation of cardiotoxic drugs).
• Address precipitating factors of decompensation: infection, arrhythmias, uncontrolled hypertension, non‑adherence, high salt intake, renal dysfunction.
• Implement guideline‑directed medical therapy (GDMT), especially for HFrEF.
• Provide patient education regarding fluid/salt restriction, weight monitoring, medication adherence, and when to seek review.^[7]

Lifestyle and Non‑Pharmacologic Measures

• Dietary sodium restriction: Moderate restriction (e.g., <2–3 g/day) to prevent fluid retention.
• Fluid management: Fluid restriction in significant hyponatremia or severe congestion.
• Weight monitoring: Daily weights to detect early fluid accumulation.
• Exercise and rehabilitation: Regular, supervised exercise improves functional capacity and quality of life.
• Vaccinations: Influenza and pneumococcal vaccines to reduce infections that may precipitate decompensation.
• Avoid harmful substances: Limit alcohol, stop smoking, avoid NSAIDs and other drugs that worsen HF or renal function.

Pharmacologic Therapy – HFrEF (LVEF < 40%)

For symptomatic chronic HFrEF, core therapies target neurohormonal activation and remodeling.

• ACE inhibitors (ACEi) or ARBs:
  • Reduce mortality and hospitalizations by inhibiting RAAS, decreasing afterload and preload, and limiting remodeling.
  • Used in all suitable HFrEF patients unless contraindicated.
• Angiotensin receptor–neprilysin inhibitor (ARNI):
  • Sacubitril/valsartan replaces ACEi/ARB in eligible symptomatic HFrEF patients; enhances natriuretic peptide activity plus RAAS blockade.
• Evidence‑based beta‑blockers:
  • Bisoprolol, carvedilol, or metoprolol succinate reduce mortality and hospitalizations by counteracting chronic SNS activation.
  • Initiate in stable euvolemic patients and uptitrate gradually.
• Mineralocorticoid receptor antagonists (MRA):
  • Spironolactone or eplerenone provide additional mortality and hospitalization reduction by blocking aldosterone‑mediated fibrosis and sodium retention.^[2]
• SGLT2 inhibitors:
  • Dapagliflozin and empagliflozin reduce HF hospitalizations and cardiovascular events in HFrEF, with or without diabetes, likely via natriuretic, metabolic, and renal mechanisms.^[2]
• Loop diuretics:
  • Furosemide, bumetanide, or torsemide relieve congestion by promoting natriuresis.
  • Titrate to achieve euvolemia; do not use diuretics alone as disease‑modifying therapy.
• Additional agents (selected patients):
  • Hydralazine + isosorbide dinitrate: For HFrEF patients who remain symptomatic despite optimal therapy, particularly with ACEi/ARB/ARNI intolerance, and has strong evidence in some ethnic groups.
  • Ivabradine: For sinus rhythm with elevated heart rate despite maximally tolerated beta‑blocker in selected HFrEF patients.
  • Digoxin: May reduce hospitalizations and control rate in AF but does not improve survival.

Pharmacologic Therapy – HFpEF and HFmrEF

• HFpEF:
  • No single therapy has shown a large mortality benefit comparable to HFrEF.
  • Focus on controlling blood pressure, treating ischemia and AF, managing volume overload (loop diuretics), and aggressive treatment of comorbidities (obesity, diabetes, sleep apnea).
  • SGLT2 inhibitors have emerging evidence for reduction in HF hospitalizations and are increasingly used.
• HFmrEF:
  • Often managed similarly to HFrEF, as many therapies show benefit in this range.

Device and Interventional Therapies

• Implantable cardioverter–defibrillator (ICD):
  • For primary or secondary prevention of sudden cardiac death in selected HFrEF patients (reduced EF despite optimal medical therapy, adequate life expectancy).
• Cardiac resynchronization therapy (CRT):
  • Biventricular pacing improves symptoms, LV function, and survival in patients with HFrEF, reduced EF, and wide QRS with LBBB pattern.
• Revascularization:
  • PCI or CABG for significant coronary disease contributing to ischemic cardiomyopathy.
• Valvular interventions:
  • Surgical or transcatheter procedures (e.g., TAVR, MitraClip) for significant valvular lesions driving HF.
• Advanced therapies:
  • Left ventricular assist devices (LVAD) as bridge to transplant or destination therapy.
  • Orthotopic heart transplantation for selected end‑stage HF patients.

Acute Decompensated Heart Failure

Patients may present with acute pulmonary edema or cardiogenic shock. Principles include rapid assessment of airway and breathing, IV loop diuretics, vasodilators (if blood pressure permits), inotropes for low output states, and management of precipitating causes (e.g., acute coronary syndrome, hypertensive emergency, arrhythmia).^[7]

Comorbidity and Risk Management

• Hypertension: Tight control reduces HF risk and progression.
• Coronary artery disease: Aggressive secondary prevention and revascularization where appropriate.
• Diabetes: Optimize glycemic control; SGLT2 inhibitors have cardiorenal benefits in HF and T2DM.^[1]
• CKD: Monitor renal function and potassium closely, especially with RAAS inhibitors and MRAs; hyperkalemia management is critical and often involves careful monitoring and targeted therapies.^[4]
• Atrial fibrillation: Rate or rhythm control and anticoagulation as indicated.

Key Clinical Pearls

• Think HF in any older patient with progressive dyspnea, orthopnea, or exercise intolerance, especially with a history of MI, hypertension, or valvular disease.
• BNP/NT‑proBNP are powerful tools to help rule out HF when low and to risk‑stratify patients when elevated, but interpret levels in context of age, renal function, and obesity.^[7]
• Echocardiography is essential in all suspected HF cases to determine EF, identify structural disease, and guide therapy.
• HFrEF treatment is neurohormonal blockade‑centered: ACEi/ARB/ARNI, beta‑blocker, MRA, and SGLT2 inhibitor form the core disease‑modifying therapies.
• Loop diuretics are for symptom control (congestion) and should be used alongside, not instead of, GDMT.
• Check for and treat reversible causes/precipitants such as ischemia, arrhythmias, uncontrolled hypertension, infection, anemia, and thyroid disease.
• Chronic HF is a multisystem syndrome: watch for and manage renal dysfunction, hepatic congestion, sarcopenia/malnutrition, depression, and cognitive impairment in elderly patients.^[6]
• Hyperkalemia and renal dysfunction often limit RAASi/MRA use; close monitoring and modern potassium management strategies can enable continuation of prognostically important drugs.^[4]
• Right‑sided signs (JVD, edema, hepatomegaly) point to systemic venous congestion; always look carefully at the neck veins and abdomen.
• Advanced HF requires early referral to HF specialists for consideration of device therapy, LVAD, or transplantation.

Summary

Heart failure is a common and complex clinical syndrome resulting from diverse cardiac pathologies and maladaptive neurohormonal activation. A solid understanding of its pathophysiology, clinical presentation, and evidence‑based management is essential for medical students and clinicians alike. Combining foundational pharmacologic therapies, lifestyle measures, device interventions, and comorbidity management can substantially improve symptoms, reduce hospitalizations, and prolong survival in patients with HF.^[7]

Suggested Next Steps for Study

• Review major HF trials (e.g., those establishing ACEi, beta‑blockers, MRAs, ARNIs, and SGLT2 inhibitors).
• Practice classifying HF cases by EF (HFrEF vs HFpEF) and NYHA class in clinical vignettes.
• Work through sample exam questions focusing on diagnosis, GDMT selection, and decompensated HF management.